Synthesis and biological evaluation of novel peptidomimetic inhibitors of the coronavirus 3C-like protease
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and related variants, are
responsible for the devastating coronavirus disease 2019 (COVID-19) pandemic. The SARS …
responsible for the devastating coronavirus disease 2019 (COVID-19) pandemic. The SARS …
A review of the latest research on M pro targeting SARS-COV inhibitors
H Yang, J Yang - RSC Medicinal Chemistry, 2021 - pubs.rsc.org
Since the outbreak of COVID-19, the pandemic caused by SARS-CoV-2 infection is still
spreading at an alarming rate and has caused huge loss of life and economic damage …
spreading at an alarming rate and has caused huge loss of life and economic damage …
[HTML][HTML] Recent changes in the mutational dynamics of the SARS-CoV-2 main protease substantiate the danger of emerging resistance to antiviral drugs
L Parigger, A Krassnigg, T Schopper, A Singh… - Frontiers in …, 2022 - frontiersin.org
The current coronavirus pandemic is being combated worldwide by nontherapeutic
measures and massive vaccination programs. Nevertheless, therapeutic options such as …
measures and massive vaccination programs. Nevertheless, therapeutic options such as …
[HTML][HTML] Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors
L Song, S Gao, B Ye, M Yang, Y Cheng, D Kang… - … Pharmaceutica Sinica B, 2023 - Elsevier
The main protease (M pro) of SARS-CoV-2 is an attractive target in anti-COVID-19 therapy
for its high conservation and major role in the virus life cycle. The covalent M pro inhibitor …
for its high conservation and major role in the virus life cycle. The covalent M pro inhibitor …
Perspectives on SARS-CoV-2 main protease inhibitors
The main protease (Mpro) plays a crucial role in severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) replication and is highly conserved, rendering it one of the …
coronavirus 2 (SARS-CoV-2) replication and is highly conserved, rendering it one of the …
Evolutionary and structural insights about potential SARS-CoV-2 evasion of nirmatrelvir
The US FDA approval of PAXLOVID, a combination therapy of nirmatrelvir and ritonavir has
significantly boosted our morale in fighting the COVID-19 pandemic. Nirmatrelvir is an …
significantly boosted our morale in fighting the COVID-19 pandemic. Nirmatrelvir is an …
Discovery of PLpro and Mpro Inhibitors for SARS-CoV-2
There are very few small-molecule antivirals for SARS-CoV-2 that are either currently
approved (or emergency authorized) in the US or globally, including remdesivir …
approved (or emergency authorized) in the US or globally, including remdesivir …
Identification of mutation resistance coldspots for targeting the SARS‐CoV2 main protease
N Krishnamoorthy, K Fakhro - IUBMB life, 2021 - Wiley Online Library
Mutations in the novel coronavirus SARS‐CoV2 are the major concern as they might lead to
drug/vaccine resistance. In the host cell, the virus largely depends on the main protease …
drug/vaccine resistance. In the host cell, the virus largely depends on the main protease …
An extended conformation of SARS-CoV-2 main protease reveals allosteric targets
Z Sun, L Wang, X Li, C Fan, J Xu… - Proceedings of the …, 2022 - National Acad Sciences
The coronavirus main protease (Mpro) is required for viral replication and has enzymatical
activity as a homodimer. Thus, targeting its dimerization is an effective strategy for …
activity as a homodimer. Thus, targeting its dimerization is an effective strategy for …
Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir
Y Duan, H Zhou, X Liu, S Iketani, M Lin, X Zhang… - Nature, 2023 - nature.com
Nirmatrelvir is a specific antiviral drug that targets the main protease (Mpro) of SARS-CoV-2
and has been approved to treat COVID-19,. As an RNA virus characterized by high mutation …
and has been approved to treat COVID-19,. As an RNA virus characterized by high mutation …